Skip to content
Buy This GLP
← Research
Formats

Weight-Loss Treatment Compared: Surgery, GLP-1 Drugs and Other Options

Bariatric surgery was associated with more weight loss in a large records study. Treatment risks, ongoing care and access also matter.

Editorial profile: Neil SandersBuy This GLP Editorial Team3 min read
What happens outside a trialmetabolic bariatric surgerygreatest and most durable — substantially underusedincretin drugslarge in trials, smaller in practiceendoscopic sleeve gastroplastymoderate, durable, few serious eventsintensive lifestyle programsabout 5%, with regain after the program endsolder weight medicationspoor persistence despite lower cost

A medical-record study found more weight loss after bariatric surgery than after starting GLP-1 drugs [1]. A separate comparison of cardiovascular outcomes after surgery and semaglutide focused on heart and vascular events. The studies tracked different outcomes.

What the surgery comparison found

The study included 44,025 patients. At two years, estimated weight loss was 22.4% after sleeve gastrectomy and 28.1% after gastric bypass. Estimates were 6.5% with semaglutide and 10.8% with tirzepatide [1].

Treatment was not randomly assigned. Differences in why people chose each treatment may affect the results. Medication doses, treatment duration and follow-up also varied.

Why results vary outside trials

A review of routine care found that tolerability and access can affect how long patients stay on treatment [2]. Studies of GLP-1 treatment persistence help explain why a trial and a health record cohort can produce different weight estimates.

The review also considered structured lifestyle programs, endoscopic procedures and other medicines. Those data come from studies with different patients and follow-up periods. A comparison of averages cannot identify the best treatment for every patient.

Frequently asked

Which option was associated with the most weight loss?
Gastric bypass had the highest average weight loss among the treatments in this observational cohort. The study did not assign treatments randomly.

Sources

  1. [1] Brown A, Patel SS, Kozato A, et al. (2026). Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery Obesity. Source
  2. [2] Kassem S, et al. (2026). Real-World Evidence for Existing Anti-Obesity Therapies Diabetes, Obesity and Metabolism. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Formats